Skip to main content

Ilumya Side Effects

Generic name: tildrakizumab

Medically reviewed by Philip Thornton, DipPharm. Last updated on Jan 8, 2023.

Note: This document contains side effect information about tildrakizumab. Some dosage forms listed on this page may not apply to the brand name Ilumya.

Applies to tildrakizumab: subcutaneous solution.

Serious side effects of Ilumya

Along with its needed effects, tildrakizumab (the active ingredient contained in Ilumya) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking tildrakizumab:

More common

Incidence not known

  • Itching skin
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals

Other side effects of Ilumya

Some side effects of tildrakizumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

  • Bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
  • diarrhea


For Healthcare Professionals

Applies to tildrakizumab: subcutaneous solution.


Frequency not reported: Hypersensitivity, angioedema, urticaria[Ref]


Very common (10% or more): Infections (e.g., upper respiratory tract infection) (23%)[Ref]


Common (1% to 10%): Injection site reactions (e.g., injection site urticaria, pruritus, pain, reaction, erythema, inflammation, edema, swelling, bruising, hematoma, hemorrhage)[Ref]


Very common (10% or more): Upper respiratory tract infections (e.g., nasopharyngitis, upper respiratory tract infection, viral upper respiratory tract infection, pharyngitis) (14%)[Ref]

Frequently asked questions


1. "Product Information. Ilumya (tildrakizumab)." Merck & Co., Inc (2018):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.